Vident Advisory LLC purchased a new stake in Envista Holdings Corporation (NYSE:NVST - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 25,728 shares of the company's stock, valued at approximately $444,000.
Several other large investors have also added to or reduced their stakes in the business. UMB Bank n.a. grew its holdings in Envista by 214.4% during the first quarter. UMB Bank n.a. now owns 2,094 shares of the company's stock valued at $36,000 after purchasing an additional 1,428 shares during the period. Palouse Capital Management Inc. raised its stake in shares of Envista by 14.4% during the first quarter. Palouse Capital Management Inc. now owns 9,444 shares of the company's stock valued at $163,000 after acquiring an additional 1,186 shares during the last quarter. FourThought Financial Partners LLC purchased a new position in shares of Envista during the first quarter valued at about $180,000. Vestcor Inc purchased a new stake in Envista in the first quarter worth about $211,000. Finally, Aigen Investment Management LP purchased a new stake in Envista in the first quarter worth approximately $274,000.
Envista Stock Up 3.7%
Shares of NYSE:NVST traded up $0.76 during midday trading on Thursday, reaching $21.53. The company had a trading volume of 728,243 shares, compared to its average volume of 2,493,235. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.44 and a quick ratio of 2.08. Envista Holdings Corporation has a one year low of $14.22 and a one year high of $23.00. The stock's fifty day moving average price is $20.50 and its 200-day moving average price is $18.58. The stock has a market capitalization of $3.58 billion, a P/E ratio of 67.28, a PEG ratio of 1.11 and a beta of 0.99.
Envista (NYSE:NVST - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.02. The business had revenue of $682.10 million during the quarter, compared to the consensus estimate of $638.21 million. Envista had a net margin of 2.11% and a return on equity of 4.84%. The company's quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.11 earnings per share. Envista has set its FY 2025 guidance at 1.050-1.15 EPS. Equities research analysts expect that Envista Holdings Corporation will post 1 earnings per share for the current fiscal year.
Analyst Ratings Changes
NVST has been the topic of several recent analyst reports. Piper Sandler raised their price objective on shares of Envista from $17.00 to $19.00 and gave the company a "neutral" rating in a research report on Friday, August 1st. Evercore ISI lifted their price target on shares of Envista from $19.00 to $23.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Robert W. Baird raised shares of Envista from a "neutral" rating to an "outperform" rating and upped their price target for the stock from $21.00 to $23.00 in a research report on Tuesday, May 27th. Wall Street Zen lowered shares of Envista from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 30th. Finally, Stifel Nicolaus boosted their price target on shares of Envista from $24.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Envista currently has an average rating of "Hold" and a consensus price target of $20.92.
Read Our Latest Research Report on NVST
About Envista
(
Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Read More

Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.